TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 positive~* Naïve to antiretroviral therapy including investigational antiretroviral agents~* Not of reproductive potential or, if of reproductive potential agrees to 1) true abstinence, or 2) use of an acceptable method of birth control during the study~Exclusion Criteria:~* Use of recreational or illicit drugs or has recent history of drug or alcohol abuse or dependence~* Has been treated for a viral infection other than HIV-1 (such as hepatitis B) with an agent that is active against HIV-1 including but not limited to adefovir, tenofovir, entecavir, emtricitabine, or lamivudine~* Has documented or known resistance to raltegravir, emtricitabine, and/or tenofovir before the first dose of study drug~* Has participated in a study with an investigational compound or device within 30 days or anticipates participating in such a study during this study~* Has used systemic immunosuppressive therapy or immune modulators within 30 days or is anticipated to need them during the study (short courses of corticosteroids are allowed)~* Requires or is anticipated to require any of the following prohibited medications while in the study: phenobarbital, phenytoin, rifampin, rifabutin, or calcium, magnesium and aluminum containing antacids, such as TUMS™, Maalox™ and Milk of Magnesia™~* Has significant hypersensitivity or other contraindication to any of the components of the study drugs~* Has current, active diagnosis of acute hepatitis due to any cause~* Is pregnant, breastfeeding, or expecting to conceive during the study~* Female participant expecting to donate eggs or male participant expecting to donate sperm during the study~* Is or has a family member (spouse or children) who is investigational staff or sponsor staff directly involved in this trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Reformulated Raltegravir (Type: EXPERIMENTAL): Reformulated raltegravir 1200 mg (2x 600 mg tablets) orally once daily plus placebo to raltegravir 1 tablet orally twice daily plus TRUVADA™ orally once daily for 96 weeks
- Raltegravir (Type: ACTIVE_COMPARATOR): Raltegravir 400 mg tablet orally twice daily plus placebo to reformulated raltegravir 2 tablets orally once daily plus TRUVADA™ orally once daily for 96 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Diclofenac Sodium Gel in Knee Osteoarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Key Inclusion criteria~* Osteoarthritis of the knee Key Exclusion criteria~* Other rheumatic disease, such as rheumatoid arthritis~* Active gastrointestinal ulcer during the last year~* Known allergy to analgesic drugs

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Circadin® 2 mg in the Treatment of Primary Insomnia Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female and aged 18-80 years.~* Are willing to take a 6-SMT level evaluation test.~* Suffering from primary insomnia according to DSM-IV. criteria (307.42 primary insomnia, Appendix 24.3) .~* Sleep latency of at least 20 minutes.~* Have not been using benzodiazepines (BZD) and non-BZD hypnotics for the past 2 weeks or more.~* Have not been using psychotropic treatments for the past 3 months or more.~* Are stabilized on non-psychotropic treatments for more than 1 month.~* Are willing to sign a written informed consent to participate in the study.~Exclusion Criteria:~* Use of benzodiazepines or other hypnotics (including psychotropic treatments) during the study and preceding two weeks.~* Alcohol intake more than 30 g of pure alcohol per day and any intake after lunch-time.~* Pharmacological immunosuppression.~* Participation in a clinical trial with any investigational agent within two months prior to study enrollment.~* According to DSM IV, subjects belonging to the following groups are excluded: 780.59 (breathing related sleep disorder); 307.45 (circadian rhythm sleep disorder); 307.47 (dyssomnia not otherwise specified); 780.xx (sleep disorder due to general medical condition).~* Severe neurological, psychiatric disorders (especially psychosis, anxiety and depression) and alcoholism.~* Other serious diseases that could interfere with patient assessment.~* Pregnant or breast feeding women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Circadin (Type: EXPERIMENTAL): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TB Immunotherapy Trial With Heat-killed M. Vaccae

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* confirmed diagnosis of TB~* sputum smear positive~Exclusion Criteria:~* pregnant~* likely to be non-compliant due to drug and/or alcohol abuse~* mentally unfit to comply with treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- V7: Heat-inactivated M. vaccae pill (Type: EXPERIMENTAL): Daily pill of V7 together with standard tuberculosis therapy
- Placebo pill (Type: PLACEBO_COMPARATOR): one pill of placebo pill once per day together with standard of care TB drugs

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oral Pilocarpine in the Treatment of the Dry Eye of Patients With Sjogrens Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with Sjögren's syndrome, both in primary and secondary forms, whose diagnoses were established according to the criteria defined by the - American-European Consensus for the diagnosis of Sjögren's syndrome.~* Patients with the secondary form of the syndrome, collagen disease considered controlled by a rheumatologist, before the start of the trial and stable until the end of the study.~* Systemic therapy instituted up to two months before the beginning of the protocol.~* Literate patients.~* Signature of the informed consent form~Exclusion Criteria:~* Eye or eyelid surface disease not attributed to Sjogren's syndrome.~* Temporary or permanent occlusion of tear points.~* Use of contact lenses.~* Use of systemic medication that is known to influence tear flow.~* Need to modify the systemic treatment of the underlying disease during the trial.~* Pregnancy or breastfeeding.~* Known hypersensitivity reaction to pilocarpine hydrochloride.~* Severe cardio-pulmonary disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Pilocarpine Hydrochloride (Type: EXPERIMENTAL): Patients with Sjögren's syndrome were allocated to receive oral pilocarpine 20mg per day, (5mg every 6 hours, for ten weeks.
- placebo (Type: PLACEBO_COMPARATOR): Patients with Sjögren's syndrome were allocated to receive placebo administered in the same way (1 tablet every 6 hours), for ten weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Primary Inclusion criteria:~* diagnosis of idiopathic pulmonary fibrosis~* 40 to 80 years of age~* Forced Vital Capacity ≥ 50% predicted value~* carbon monoxide diffusing capacity (DLco) ≥ 35% predicted value~* either Forced Vital Capacity or carbon monoxide diffusing capacity (DLco) ≤ 90% predicted value~* no improvement in past year~* able to walk 150 meters in 6 minutes and maintain saturation ≥ 83% while on no more than 6 liters per minute supplemental oxygen~Primary Exclusion criteria:~* unable to undergo pulmonary function testing~* evidence of significant obstructive lung disease or airway hyper-responsiveness~* in the clinical opinion of the investigator, the patient is expected to need and be eligible for a lung transplant within 72 weeks of randomization~* active infection~* liver disease~* cancer or other medical condition likely to result in death within 2 years~* diabetes~* pregnancy or lactation~* substance abuse~* personal or family history of long QT syndrome~* other IPF treatment~* unable to take study medication~* withdrawal from other IPF trials

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 2403 mg/day pirfenidone (Type: ACTIVE_COMPARATOR): 2403 mg/day pirfenidone dose group.
- placebo (Type: PLACEBO_COMPARATOR): Placebo equivalent.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Efficacy and Safety Evaluation of Irbesartan and Amlodipine Combined Therapy in Essential Hypertension Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who are 19 years or older on screening~* Signed informed consent~* Patients with Essential Hypertension~* Other inclusion applied~Exclusion Criteria:~* Orthostatic hypotension~* Other exclusion applied

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Irbesartan/Amlodipine low (Type: EXPERIMENTAL): None
- Irbesartan/Amlodipine high (Type: EXPERIMENTAL): None
- Irbesartan (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial~* Male or female, aged equal to or greater than 18 years at the time of signing informed consent~* Type 1 diabetes mellitus (as diagnosed clinically) 12 months or longer prior to Visit 1 (i.e. screening)~* Treatment with basal bolus or CSII (continuous subcutaneous insulin infusion, insulin pump) treatment 6 months or longer prior to Visit 1 (i.e. screening)~* Stable insulin treatment 3 months or longer prior to Visit 1 (i.e. screening), as judged and documented by the investigator~* HbA1c 7.0-10.0 percent (Diabetes Control and Complications Trial (DCCT)), both inclusive, by central laboratory analysis (Visit 1, screening) corresponding to 53-86 mmol/mol (International Federation of Clinical Chemistry (IFCC))~Exclusion Criteria:~* Prior use of glucagon-like peptide-1 (GLP-1) receptor agonist or dipeptidyl peptidase IV (DPPIV) inhibitors~* Use of any medication, which in the investigator's opinion could interfere with the glycaemic control (e.g. systemic corticosteroids, pramlintide (Symlin®)) or affect the subject's safety. Premix insulin is not allowed~* Known proliferative retinopathy or maculopathy requiring acute treatment~* Severe neuropathy, in particular autonomic neuropathy, i.e. gastroparesis, as judged by the investigator~* Uncontrolled/untreated blood pressure at screening (Visit 1) (after resting for 5 minutes) while sitting greater than 160 mmHg for systolic or greater than 100 mmHg for diastolic (repeated measurement at Visit 2 (prior to performing the trial related activities) is allowed to exclude white-coat hypertension)~* History of acute or chronic pancreatitis~* Screening (Visit 1) calcitonin value equal to or greater than 50 ng/L

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Liraglutide 1.8 mg + insulin (Type: EXPERIMENTAL): None
- Liraglutide 1.2 mg + insulin (Type: EXPERIMENTAL): None
- Liraglutide 0.6 mg + insulin (Type: EXPERIMENTAL): None
- Liraglutide placebo 0.3 ml + insulin (Type: PLACEBO_COMPARATOR): None
- Liraglutide placebo 0.2 ml + insulin (Type: PLACEBO_COMPARATOR): None
- Liraglutide placebo 0.1 ml + insulin (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Linking Infectious and Narcology Care-Part II

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older~* HIV infected~* Hospitalized at narcology hospital~* History of injection drug use~* Current diagnosis of opioid use disorder~* Provision of information for 2 contacts to assist with follow-up~* Address within 100 kilometers of St. Petersburg~* Possession of a telephone (home or cell)~* Able and willing to comply with all study protocols and procedures~Exclusion Criteria:~* Not fluent in Russian~* Cognitive impairment~* Pregnancy, planning to become pregnant, or breastfeeding~* ART use in past 30 days prior to hospitalization~* Known hypersensitivity to naltrexone~* Acute severe psychiatric illness (i.e. ,answered yes to any of the following: past three month active hallucinations; mental health symptoms prompting a visit to the ED or hospital; mental health medication changes due to worsening symptoms; presence of suicidal ideations)~* Known history of liver failure~* ALT or AST \>5 times the upper limit of normal~* Known severe thrombocytopenia (\<50k)~* Known coagulation disorder/taking anticoagulation medications~* Body habitus that precludes intramuscular injection~* Known hypersensitivity to naloxone~* Known history of Raynaud's disease~* Known history of Itsenko-Cushing syndrome~* Known history of generalized mycoses~* Known history of glaucoma~* Known history of osteoporosis.~* Planned surgeries in the next 12 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LINC-II (Type: EXPERIMENTAL): LINC-II is a multi-faceted intervention combining pharmacological therapy (i.e., ART and naltrexone for opioid use disorder) and 12 months of strengths-based case management delivered to coordinate care across the narcology and HIV health care systems.
- Standard of Care (Type: NO_INTERVENTION): Participants randomized to the control group will receive the narcology hospital's standard of care, which is detoxification with or without stabilization. Prior to discharge, those identified as HIV-infected are given contact details for an HIV clinic, not an appointment. Upon discharge, patients are encouraged to receive outpatient narcology treatment, monthly, for 1 year. For this study, with regard to linkage to HIV medical care, patients will be given printed information about where to obtain HIV medical care and a resource card containing harm reduction information.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Single Dose Ciprofloxacin in the Treatment of Childhood Cholera:Randomized Controlled Clinical Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Age: 2-15 years. Gender: male. Duration of illness: \<24 hours. Written informed consent for participation in the study from either of the parents, or guardian, and oral assent from children aged ³ 8 years.~Severe dehydration according to World Health Organisation (WHO) guidelines. Positive stool dark field microscopic examination for V. cholerae.~Exclusion Criteria:~History of receiving any antimicrobial agent (including study drugs) effective in the treatment of V. cholerae within 72 hours of screening.~Concomitant infection(s) requiring antimicrobial therapy. A concomitant illness that may interfere with the evaluation of outcome or safety of the study drugs.~Patients with known chronic renal insufficiency. \[As all cholera patients with moderate to severe dehydration have pre-renal insufficiency on admission, and as it is not possible to detect whether a patient has renal failure until the patient has been hydrated for at least 24 hours, serum creatinine will be checked 24 hours post-administration of first dose of study medication, on Day 5, and at any time as clinically indicated. (If the baseline creatinine is \> 200 mcmol/L, any patient with creatinine \> than 200 mcmol/L 24 hours post-administration, will be considered as suffering from renal failure and will be withdrawn from the trial.) Patients with known cardiac or hepatic impairment, i.e. SGOT/SGPT or bilirubin \> 3 times the upper limit of normal, and patients with a history of central nervous system (CNS) disorders (known risk of experiencing seizures, a history of convulsive disorders or head injury trauma, currently on anti-seizure medication or within two months post-stroke).~Patients previously enrolled in the study. Patients participating in any clinical study within one month prior to study entry.~Patients' known to have AIDS. Patients treated with quinolones in the 14 days prior to the study. Patients known to have underlying rheumatological disease, joint problems, etc. Patients with a known hypersensitivity to any of the study drug regimens or related compounds (including fluoroquinolones and macrolides).~Female patients who are lactating, or are sexually active and using unreliable contraception.~Patients having a known underlying rheumatological disease, joint problems secondary to trauma or pre-existing conditions known to be associated with arthropathy.~Patients with conditions precluding the performance of a reliable series of musculoskeletal examinations are to be excluded from trial participation.

- Gender: MALE
- Minimum Age: 2 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SMaRT Blood: Single-unit Versus Multiple-unit Packed Red Blood Cell Transfusion in Non-acute Postpartum Anemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women over 18~* Willing and stable to give consent~* \> 6 hours postpartum from any mode of delivery~* Determined by their physician to require blood transfusion either by:~  * Hb \<7g/dL OR~ * \>7g/dL with any sign or symptom of anemia such as fatigue, dizziness, tachycardia, or hypotension~* Agreed to accept blood transfusion~* No contraindications to blood transfusion~Exclusion Criteria:~* hemoglobinopathies~* patients with an ejection fraction \<35%~* Hb \<5 g/dL~* HR \> 130 bpm, BP \< 80/40

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single-Unit Blood Transfusion Protocol (Type: ACTIVE_COMPARATOR): In this arm, patients receive a 1 unit pRBC transfusion with the plan for post-transfusion blood count at 4-6 hours post-transfusion and clinical reassessment.
- Multiple-Unit Blood Transfusion Protocol (Type: ACTIVE_COMPARATOR): In this arm, patients receive 2 units of pRBCs, followed by 4-6 hour post-transfusion blood count and clinical reassessment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients at least 19 years of age scheduled for outpatient contrast enhanced abdominal pelvic CT at The Kirklin Clinic in Birmingham Alabama as part of clinical care with the patient's provider will be screened for eligibility.~Exclusion Criteria:~* Not competent to give consent.~* Pregnant.~* Known allergy to either of the contrast agents.~* Loss of sense of taste or smell.~* Contraindication to oral administration such as aspiration risk.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Gastroview
- 2 (Type: EXPERIMENTAL): Omnipaque

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete